“exondys-51” Archives

in
Entry Author Date Location
Lax Approval Requirements Yield Blockbusters That Don’t Work 03/13/20 National
FDA Rejects Sarepta’s Second Duchenne Drug, Citing Safety Concerns 08/19/19 Boston
Bio Roundup: Zolgensma Fallout, Duchenne Redux, Ebola Boost & More 08/16/19 National
Four New Drugs Are Around the Corner. Here’s What You Need to Know. 08/15/19 National
Duchenne Advocates Start Casimir, Aiming to Capture Missing Data 07/26/19 Boston
With Its First Human Data, Solid Slips in Duchenne Gene Therapy Race 02/07/19 Boston
Bio Roundup: 2019 Trials, Pilgrim Price Chat, Pre-Xmas Sales & More 12/21/18 National
Sarepta Touts New Data and a “Signal” With Duchenne Gene Therapy 10/03/18 Boston
Europe Advisory Panel Rejects Sarepta’s Duchenne Drug Once Again 09/21/18 Boston
Sarepta’s Data Are First in Rush for Duchenne Gene Therapy 06/19/18 Boston
Bio Roundup: IDO Fallout, Express Scripts Dumps Amgen, Isaly Out & More 05/04/18 National
Life Sci Veteran Garabedian Talks Up Biotech Accelerator in Texas 04/23/18 Texas
Solid Discloses Duchenne Problems in IPO & Raises Rival’s Hackles 01/25/18 Boston
Ed Kaye on Sarepta’s Duchenne Quest, Rising to CEO & His New Startup 11/20/17 Boston
With $40M for Exonics, Duchenne’s Gene Therapy, CRISPR Race Heats Up 11/08/17 Boston
FDA Panel Pans PTC’s Audacious Plan to Force Vote on Duchenne Drug 09/28/17 New York
Bio Roundup: GOP Drama, Immunotherapy Setbacks, Pharma Revamps 07/28/17 National
After Sarepta’s Surprising FDA Nod, CEO Kaye Plans to Resign 04/28/17 Boston
Duchenne, SMA, and the Rise of Patient Power at “What’s Hot” on May 11 04/27/17 Boston
Next Stop on Father’s Duchenne Quest: Wall Street? Solid Raises $50M 03/30/17 Boston
After a Clinical Trial Death, FDA OKs New Tests of Akashi’s Duchenne Drug 03/22/17 Boston
Nonprofit Seeds Exonics to Fund Push For CRISPR Duchenne Treatment 02/27/17 Boston
Cashing in On Duchenne Approval, Sarepta Sells Voucher to Gilead For $125M 02/21/17 Boston
His Gene Therapy Near Approval, Spark CEO Wonders: What Price Vision? 02/16/17 New York
Anthem Caps Coverage Of Biogen Spine Drug Despite Wide FDA Approval 01/24/17 Boston
Ex-FDA Commish Califf Gives Props to Patient Groups—With Caveats 01/23/17 National
Biotech Roundup: JPM Deals, Gender Diversity, PCSK9 Battle & More 01/13/17 National
Notes From The JPM ’17 Vortex: Trump, Rainstorms & The Price You Pay 01/13/17 National
CEO Kaye Details Insurance Battle As Sarepta Launches Duchenne Drug 01/10/17 Boston
Biogen Sets $750,000 Initial Price For First-Ever Spinal Atrophy Drug 12/28/16 Boston
Page 1 of 2 next page »